Slide 1: Electromed, Inc. Investor Presentation
Electromed, Inc. Investor Presentation November 12, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies
Slide 2: Forward Looking Statements
Forward Looking Statements: Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “
Slide 3: Electromed – Who We Are
Electromed – Who We Are - Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. Headquarters: New Prague, MN Ticker: ELMD Established: 1992 Annual Revenue: $66.2M (As of
Slide 4: Electromed Highlights
Electromed Highlights: ● Growing and profitable medical technology company ● A leader in the large and expanding airway clearance market ● The SmartVest® Airway Clearance System’s High Frequency Chest Wall Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement
Slide 5: What is Bronchiectasis (BE)?
What is Bronchiectasis (BE)? ● Irreversible lung condition characterized by abnormal widening of one or more of the bronchi (airways) ● Repeated episodes of pulmonary inflammation and infection leads to mucus accumulating in the airways ● Mean prevalence of bronchiectasis in patients with COPD is 54
Slide 6: U.S. Market: Large, Growing, Underpenetrated
U.S. Market: Large, Growing, Underpenetrated Estimated HFCWO bronchiectasis penetration, treated population 3 Estimated Net Bronchiectasis prevalence, DIAGNOSED 1 Estimated bronchiectasis prevalence, UNDIAGNOSED with COPD/BE overlap 2 Bronchiectasis HFCWO penetration ~16% 3 Diagnosed BE population g
Slide 7: How is Bronchiectasis Treated?
How is Bronchiectasis Treated? Antibiotics, Anti-Inflammatories, Airway Clearance Triple down on bronchiectasis – clear airways first TM with Smarvest – treat the infection – reduce inflammation – complete bronchiectasis care
Slide 8: How is Bronchiectasis Treated? HFCWO Therapy
How is Bronchiectasis Treated? HFCWO Therapy – mimics manual chest percussion therapy (CPT) How does SmartVest HFCWO Therapy work? Air-Pulse Technology: A generator delivers repeating pulses of air through a single hose to an inflated wearable vest. Gentle squeeze and release: Each pulse gently sque
Slide 9: SmartVest Clearway: HFCWO Designed with the patient in mind
Smartvest Clearway: HFCWO Designed with the patient in mind An enhanced patient experience – sleek and light weight generator, intuitive user interface for better patient adherence, more portable and easier for travel SmartVest® has a well-established reimbursement code from CMS – E0483; We estimate
Slide 10: SmartNotes Patient Progress Report
SmartNotes Patient Progress Report – Patient outcomes and treatment progress to physicians SmartNotes combine patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management ● TeleRespiratory Services : A team of Respiratory Therapists stay conn
Slide 11: Clinical Evidence: Published Studies Showing Effectiveness of HFCWO
Clinical Evidence: Electromed has Published Studies Showing Effectiveness of HFCWO to Treat Bronchiectasis SmartVest users have reported: 95% of patients would recommend SmartVest to others, 97% of patients report feeling better or the same after SmartVest use, 98% of patients report an increase in
Slide 12: Direct-to-Patient Model: Drives attractive margin profile
Direct-to-Patient Model: Drives attractive margin profile Traditional medical equipment channel: Manufacturer > Home Medical Equipment (HME) Distributor > Patient Vs. Direct-to-Patient Distribution (Electromed): Electromed > Patient Company expects gross margins in the mid-70s and improving with the
Slide 13: Net Revenue Breakdown
Net Revenue Breakdown - $66.2M (TTM ended 9/30/2025) By Setting: 94% Home Care (includes $3.2 million from home care distributor revenue), 5% Hospitals, 1% Other Homecare by Payer: 52% Commercial/Other (includes managed Medicare and managed Medicaid), 46% Medicare, 2% Medicaid Homecare Qualified Ref
Slide 14: Growth Strategy: How will Electromed increase market share?
Growth Strategy: How will Electromed increase market share? ● Continued sales force expansion along with complementary infrastructure investments ● Increase brand awareness and revenue with direct-to-consumer and physician marketing ● Market development to improve diagnosis rates and evidence to sup
Slide 15: Long-term objectives
Long-term objectives: Electromed is committed to delivering long-term profitable growth Double-digit revenue growth: Increase market share, deeper penetration of current SmartVest prescribers Operating Margin Improvement: Operating leverage as revenue increases
Slide 16: Capital Allocation Strategy
Capital Allocation Strategy: Proven execution against out priorities Capital Allocation > Organic Business Growth > Generate Free Cash Flow > Potential Strategic Investments or Return to Shareholders 2025 Execution: ● New CRM & CAPEX investments ● Sales rep expansion ● Market development ● Triple Do
Slide 17: Why invest?
Why invest? ● Large, expanding chronic lung diseases market ● Clinically proven technology ● Broad payor coverage ● Consistent double-digit organic revenue growth ● High gross margins, robust cash flow and expanding operating leverage
Slide 18: Performance vs. Russell Medical Equipment Index
Performance vs. Russell Medical Equipment Index (TTM and as of 9/30/2025 Results) Sales Growth: ELMD 16.0% > RUS ME 15.2% Gross Margin: ELMD 78.0% > RUS ME 53.4% Operating Margin: ELMD 15.7% > RUS ME (1.8%)
Slide 19: Electromed, Inc. contacts
Electromed, Inc.: Jim Cunniff, President & CEO, 952-758-9299, jcunniff@electromed.com – Brad Nagel, CFO, 952-758-9299, bnagel@electromed.com ICR Healthcare: Mike Cavanaugh, 617-877-8641, mike.cavanaugh@icrhealthcare.com
Slide 20: Appendix
Jk (SK APPENDIX
Slide 21: Financial Highlights: Financial Summary
Financial Highlights: Financial Summary (in $ millions, except shares amounts) Three Months Ended: September 30, 2025 (unaudited) and September 30, 2024 (unaudited) Revenues: September 30, 2025: $16.9 September 30, 2024: $14.7 Gross Profit: September 30, 2025: $13.2 September 30, 2024: $11.5 Gross M